



## Studies on the Synthesis of Vitamin D Analogs with Aromatic D-Ring

SILVINA EDUARDO-CANOSA, MARÍA MARCO, RITA SIGÜEIRO and ANTONIO MOURIÑO

Laboratorio de Investigación Ignacio Ribas, Departamento de Química Orgánica, Universidad de Santiago de Compostela, Avda. Ciencias, s/n, 15782 Santiago de Compostela, Spain

*Manuscript received on September 6, 2017; accepted for publication on October 10, 2017*

### ABSTRACT

Herein, we describe our studies on the synthesis of  $1\alpha,25$ -dihydroxyvitamin D<sub>3</sub> analogs possessing a benzene ring replacing the natural 5-membered **D**-ring by the Wittig-Horner and dienyne approaches. A key feature is the synthesis of a Cr(CO)<sub>3</sub>-complexed previtamin D derivative that enables the construction of vitamin D analogs with aromatic **D**-ring through a thermal [1,7]-H sigmatropic shift. This study establishes the basis for the design of new vitamin D analogs containing aromatic **D**-ring, complexed or uncomplexed to Cr(CO)<sub>3</sub> type moieties for specific molecular recognition and drug research and development.

**Key words:** D-ring modified vitamin D analogs, aryl-Cr(CO)<sub>3</sub> complexes, cancer, sigmatropic rearrangements, synthesis.

### INTRODUCTION

$1\alpha,25$ -Dihydroxyvitamin D<sub>3</sub> [**1**, 1,25D, calcitriol, Figure 1], the most potent steroid hormone known and the active metabolite of the seco-steroid vitamin D<sub>3</sub>, interacts with the vitamin D nuclear receptor (VDR), a member of the nuclear receptor superfamily, to dimerize with the retinoid X receptor (RXR). The heterodimer binds to the vitamin D response elements (VDREs) in target gene promoters and recruit coactivator proteins to induce a cascade of events including control of mineral homeostasis and various important cellular processes such as differentiation, anti-proliferation, growth, angiogenesis, apoptosis, and immunomodulation


(Norman et al. 1979, Evans et al. 1988, Klierer et al. 1992, Bouillon et al. 1995, Feldman et al. 2011). Recently, it was discovered that 1,25D activates more than 229 genes associated with several diseases, including arthritis, diabetes and cancer, suggesting that this hormone might have an even broader range of biological functions than originally thought (Lincoln et al. 2010) 1,25D itself has clinical applications, but the pharmacological doses required for treatment of cancer induce strong, undesired hypercalcemia (Plum et al. 2010, Feldman et al. 1997). Structure-function studies of numerous 1,25D analogs have shown that the undesired calcemic effects can be reduced during cell-differentiating activities, but the mechanism of this selectivity has not yet been unraveled (Feldman et al. 2011, Glebocka et al. 2012). Increasing synthetic efforts have been directed at the

---


Correspondence to: Antonio Mouriño  
E-mail: [antonio.mourino@usc.es](mailto:antonio.mourino@usc.es)

\* Contribution to the centenary of the Brazilian Academy of Sciences.





**Figure 1** - Structures of 1,25D (**1**), calcipotriol (**2**), OCT (**3**) and target **D**-ring-aromatic compound **4**.



**Figure 2** - Retrosynthesis of target **4** by the Wittig-Horner and Dienyne approaches.

development of non-calcemic analogs of the natural hormone 1,25D for treatment of specific disorders, but only a few have found clinical applications. Among these, calcipotriol (**2**, Figure 1) and OCT (**3**), two analogs with structural modifications at the side chain, are being successfully used for treatment of psoriasis (Feldman et al. 1997). A few structural features that reduce the calcemic activity include: a) unsaturations at the side chain or **D**-ring (Verlinden et al. 2000), b) the lack of the 19-methylene group (Kensler et al. 2000), c) 14-*epi*-configuration (Verlinden et al. 2000, Ma et al. 2013), d) 3-*epi*-configuration (Molnar et al. 2011), e) short non-hydroxylated side chains (Plum et al. 2004), f) **CD**-carboranic mimics (Yamada et al. 2014) and g) *o*-carboranic side chains (Otero et al. 2016). Nonsecosteroidal vitamin D receptor modulators that reduce calcemic effects have also been reported (Eduardo-Canosa et al. 2010).

Our continued interest in the synthesis of 1,25D analogs with selective properties as potential

drugs for treatment of cancer and/or psoriasis led us to study the synthesis of aromatic compounds **4a** and **4b** (Figure 1) as models, which bear a benzene ring replacing the natural 5-membered **D**-ring. Preliminary studies to build the triene system of **4** utilizing the Wittig-Horner coupling approach (route **A**) (Lythgoe 1980) between phosphine-oxide-lithium anion **5** and ketone **6** resulted in the recovery of starting ketone presumably through the corresponding enolate (Figure 2). Attempts to synthesize **4b** through the dienyne approach (route **B**) (Castedo et al. 1986) were hampered by difficulties to accomplish the sigmatropic [1,7]-H shift on the previtamin **7**, presumably due to cross-conjugation of the triene system with the aromatic ring. Here we describe our efforts to synthesize **4a** through route **A** and **4b** through route **B**, from ketone-Cr(CO)<sub>3</sub> complex **9**. Complexation with Cr(CO)<sub>6</sub> was envisioned as a way to reduce conjugation of the aromatic ring with either the carbonyl group in tetralone **6** or the triene system in **7**.

## MATERIALS AND METHODS

### GENERAL MATERIALS AND METHODS

Reagents were purchased from Aldrich Chemical (www.sigma-aldrich.com) or Acros Organics (www.acros.com) and used without further purification. All reactions involving oxygen or moisture sensitive compounds were carried out under dry argon atmosphere using oven-dried or flame-dried glassware and standard syringe/septa techniques. All dry solvents were distilled under argon immediately prior to use: Tetrahydrofuran (THF), Et<sub>2</sub>O and *n*-Bu<sub>2</sub>O were distilled from Na/benzophenone. CH<sub>2</sub>Cl<sub>2</sub> and Ac<sub>2</sub>O were distilled from P<sub>2</sub>O<sub>5</sub>. Hexanes, *n*-heptane, diisopropylamine (*i*-PrNH<sub>2</sub>) and triethylamine (Et<sub>3</sub>N) were distilled from CaH<sub>2</sub>. MeOH was distilled from Mg/I<sub>2</sub>. DMSO was distilled from CaH<sub>2</sub> and stored over activated 4 Å molecular sieves. Solutions of *n*-butyllithium

in hexanes were titrated with *N*-benzylbenzamide before use. Hexanes refer to a distilled mixture of hexane isomers. Reaction temperatures refer to external bath temperatures. Acetone-dry ice baths were used for reactions at low temperature. Alternatively, acetone baths were cooled with a CRYOCOOL immersion cooler, provided with a temperature regulator. Organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated using rotary evaporator at aspirator pressure (20–30 mmHg). Sat refers to aqueous saturated solution. Reactions were monitored by thin-layer chromatography (TLC) using aluminum-backed Merck 60 silica gel plates (0.2 mm thickness). After visualization under ultraviolet light at 254 nm, the plates were developed by immersion in a solution containing either a mixture of *p*-anisaldehyde (2.5%), acetic acid (1%), and sulfuric acid (3.4%) in 95% ethanol or a solution of ceric ammonium nitrate (0.5 g) and ammonium molybdate (4.8 g) in H<sub>2</sub>O (100 mL) and H<sub>2</sub>SO<sub>4</sub> (5.6 mL) followed by heating with a heater gun. Flash column chromatography was performed with Merck silica gel (230–400 mesh). HPLC purifications were performed on a Shimadzu preparative liquid chromatograph, model LC-8A, equipped with a TSP 1100 UV absorbance detector using a HPLC Phenomenex-Luna silica column (Ø 25 x 250 mm 5Å~10 mm). NMR spectra were recorded in CDCl<sub>3</sub> solutions on a Bruker AMX 500 MHz, Varian Inova 400 MHz or Bruker DPX 250 MHz. Chemical shifts are reported on the δ scale (ppm) downfield from tetramethylsilane (δ = 0.0 ppm) using the residual solvent signal at δ = 7.26 ppm (<sup>1</sup>H, CDCl<sub>3</sub>) or δ = 77.0 ppm (<sup>13</sup>C, t, CDCl<sub>3</sub>) as internal standard; coupling constants (*J*) are reported in Hz. Distortionless enhancement by polarization transfer (DEPT-135) was used to assign carbon types. Low (MS) and high resolution mass spectra (HRMS) were performed in a Micromas Instruments Autospec spectrometer.

## SYNTHESIS

**1,2,3,4-Tetrahydronaphthalen-1-ol (10).** NaBH<sub>4</sub> (0.850 g, 22.45 mmol, 1.16 equiv) was added in one portion to a -78 °C cooled solution of ketone **6** (2.83 g, 19.35 mmol, 1 equiv) in MeOH (85 mL). The mixture was allowed to reach 23 °C and then concentrated *in vacuo*. The residue was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (40 mL) and washed with sat NaCl (30 mL). The organic phase was dried, filtered and concentrated *in vacuo*. The residue was purified by flash chromatography (10% EtOAc/hexanes) to give alcohols **10** (Zhao et al. 2012) [2.810 g, 18.96 mmol, 98%, colorless oil, R<sub>f</sub> = 0.56 (40% EtOAc/hexanes)]. <sup>1</sup>H-NMR (250 MHz, CDCl<sub>3</sub>): δ 7.46 (1H, m), 7.25 (2H, m), 7.16 (1H, m), 4.78 (1H, m), 2.81 (2H, m), 2.33 (1H, s), 2.11-1.73 (4H, m). <sup>13</sup>C-NMR (63 MHz, CDCl<sub>3</sub>): δ 138.7 (C), 137.0 (C), 128.8 (CH), 128.6 (CH), 127.4 (CH), 126.0 (CH), 67.9 (CH, C-1), 32.1 (CH<sub>2</sub>), 29.1 (CH<sub>2</sub>), 18.7 (CH<sub>2</sub>).

**Tricarbonyl[η<sup>6</sup>-(1,2,3,4-tetrahydronaftalen-1-ol)] chromium(0) (11).** Alcohol **10** (0.100 g, 0.67 mmol, 1.5 equiv) and Cr(CO)<sub>6</sub> (0.222 g, 1.01 mmol, 1 equiv) were dissolved in a mixture of *n*-Bu<sub>2</sub>O/*n*-heptane (8 mL, 1:1). The solution was deoxygenated. A stream of argon was passed through the solution. Dry THF (0.4 mL) was added. The reaction mixture was heated at reflux in the dark for 54 h. The mixture was allowed to reach 23 °C and filtered through a pad of celite. The solids were washed with CH<sub>2</sub>Cl<sub>2</sub> and the combined solution was concentrated *in vacuo*. The residue was purified by flash chromatography (50% CH<sub>2</sub>Cl<sub>2</sub>/hexanes) to give **11** (Schmalz et al. 1992) [74 mg, 0.26 mmol, 39%, yellow solid, R<sub>f</sub> = 0.20 (EtOAc/CH<sub>2</sub>Cl<sub>2</sub>/hexanes, 1:10:10)] and starting material **10** [40 mg, 0.27 mmol, 40%]. <sup>1</sup>H-NMR (250 MHz, CDCl<sub>3</sub>): δ 5.81 (1H, d, *J* = 6.5 Hz), 5.49 (1H, t, *J* = 6.2 Hz), 5.09 (2H, m), 4.49 (1H, m), 2.84-2.50 (2H, m), 2.23-1.85 (2H, m), 1.79-1.61 (2H, m). <sup>13</sup>C-NMR (63 MHz, CDCl<sub>3</sub>): δ 233.3

(3xC, Cr(CO)<sub>3</sub>), 113.8 (C), 112.7 (C), 95.1 (CH), 93.4 (CH), 90.1 (CH), 88.9 (CH), 66.6 (CH, C-1), 32.2 (CH<sub>2</sub>), 27.5 (CH<sub>2</sub>), 19.2 (CH<sub>2</sub>).

**Tricarbonyl- $\{\eta^6\text{-}(3,4\text{-dihydronaftalen-1(2H)-one)\}$  chromium(0) (9).** A solution of alcohol **11** (0.600 g, 2.11 mmol) in Ac<sub>2</sub>O (9 mL) and DMSO (13.5 mL) was stirred at 23 °C for 3.5 h. The reaction mixture was poured into a 0 °C cooled solution of NaOH (250 mL, 10%). The resulting mixture was extracted with Et<sub>2</sub>O (3x30 mL). The combined organic layers were dried, filtered and concentrated *in vacuo*. The residue was purified by flash chromatography [EtOAc/CH<sub>2</sub>Cl<sub>2</sub>/hexanes (1:10:10)] to give ketone **9** [0.500 g, 1.77 mmol, 84%, orange solid, R<sub>f</sub> = 0.44 (EtOAc/CH<sub>2</sub>Cl<sub>2</sub>/hexanes, 1:10:10)]. <sup>1</sup>H-NMR (250 MHz, CDCl<sub>3</sub>): δ 6.15 (1H, d, *J* = 6.6 Hz), 5.62 (1H, t, *J* = 6.1 Hz), 5.28 (1H, t, *J* = 6.3 Hz), 5.14 (1H, d, *J* = 5.4 Hz), 2.95 (1H, m), 2.71 (2H, dt, *J*<sub>1</sub> = 16.8 Hz, *J*<sub>2</sub> = 4.1 Hz), 2.43 (1H, m), 2.12 (2H, m). <sup>13</sup>C-NMR (63 MHz, CDCl<sub>3</sub>): δ 230.7 (3xC, Cr(CO)<sub>3</sub>), 196.0 (CO, C-1), 115.4 (C), 94.8 (CH), 92.6 (C), 91.2 (CH), 89.8 (CH), 89.2 (CH), 37.7 (CH<sub>2</sub>), 28.3 (CH<sub>2</sub>), 21.6 (CH<sub>2</sub>).

**(1E)-Tricarbonyl- $\{\eta^6\text{-}1,2,3,4\text{-tetrahydro-1-}[(Z)\text{-2-}((3S,5S)\text{-3,5-bis-}[(\text{triisopropylsilyloxy})\text{-2-methylenecyclohexylidene)ethylidene]\text{-naftalen}\}$  chromium(0) (12).** A solution of *n*-BuLi in hexanes (0.69 mL, 1.46 mmol, 2.1M, 2.7 equiv) was slowly added to a -78 °C cooled solution of **5** (1.10 g, 1.65 mmol, 3 equiv) in dry THF (20 mL). After 1 h, a solution of **9** (0.155 g, 0.55 mmol, 1 equiv) in dry THF (8 mL) was added via cannula. The reaction mixture was allowed to reach 15 °C. H<sub>2</sub>O (0.5 mL) were added. The mixture was concentrated *in vacuo*. The residue was dissolved in Et<sub>2</sub>O (30 mL) and successively washed with sat NaHCO<sub>3</sub> (30 mL) and sat NaCl (30 mL). The combined aqueous layers were re-extracted with Et<sub>2</sub>O (3x20 mL). The combined organic extracts were dried, filtered and concentrated *in vacuo*. The residue was purified by flash chromatography (10%

EtOAc/hexanes) to give a mixture of compounds **12** and **13** (40 mg) and the starting material **9** (99 mg, 0.35 mmol, 64%). The mixture of **12** and **13** was purified by preparative HPLC (hexanes) to afford four diastereoisomers: **12a** (3 mg, 4 μmol, 0.7%), **12b** (24 mg, 0.03 mmol, 5.5%), **13a** (2 mg, 2.7 μmol, 0.5%) and **13b** (7 mg, 0.01 mmol, 1.7%). Compound **12b**: <sup>1</sup>H-NMR (500 MHz, CDCl<sub>3</sub>): δ 6.96 (1H, d, *J* = 11.1 Hz), 6.24 (1H, d, *J* = 11.1 Hz), 5.60 (1H, m), 5.45 (1H, s), 5.30-5.24 (3H, m), 5.00 (1H, s), 4.60 (1H, m), 4.37 (1H, m), 2.78 (1H, dt, *J*<sub>1</sub> = 9.2 Hz, *J*<sub>2</sub> = 4.4 Hz), 2.68-2.53 (3H, m), 2.43-2.30 (2H, m), 2.08 (1H, m), 1.93-1.82 (3H, m), 1.15-1.03 (42H, m). <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>): δ 233.5 (3xC, Cr(CO)<sub>3</sub>), 149.2 (C), 142.3 (C), 128.8 (C), 122.5 (CH), 122.4 (CH), 111.8 (CH<sub>2</sub>), 109.5 (C), 106.6 (C), 93.8 (CH), 91.5 (CH), 91.2 (CH), 87.1 (CH), 71.1 (CH), 67.8 (CH), 46.1 (CH<sub>2</sub>), 45.1 (CH<sub>2</sub>), 29.4 (CH<sub>2</sub>), 25.7 (CH<sub>2</sub>), 22.0 (CH<sub>2</sub>), 18.2 (6xCH<sub>3</sub>), 18.1 (6xCH<sub>3</sub>), 12.4 (3xCH), 12.3 (3xCH). MS ([CI]<sup>+</sup>, *m/z*, %): 730 ([M]<sup>+</sup>, 10), 687 ([M-Pr]<sup>+</sup>, 32), 594 ([M-Cr(CO)<sub>3</sub>]<sup>+</sup>, 70), 557 ([M-OTIPS]<sup>+</sup>, 84), 247 [M-H-2xOTIPS-Cr(CO)<sub>3</sub>]<sup>+</sup>, 100). HMRS ([CI]<sup>+</sup>): calcd for: [C<sub>40</sub>H<sub>62</sub>CrO<sub>3</sub>Si<sub>2</sub>]<sup>+</sup> ([M]<sup>+</sup>): 730.3541; found: 730.3550. Compound **13b**: <sup>1</sup>H-NMR (500 MHz, CDCl<sub>3</sub>): δ 6.45 (1H, d, *J* = 11.2 Hz), 6.40 (1H, d, *J* = 11.1 Hz), 5.79 (1H, d, *J* = 6.3 Hz), 5.40 (1H, s), 5.35 (1H, m), 5.28 (2H, m), 4.99 (1H, s), 4.59 (1H, m), 4.37 (1H, m), 2.69 (2H), 2.58 (1H, d, *J* = 13.0 Hz), 2.45 (1H, m), 2.39 (2H, m), 2.01 (2H, m), 1.89 (1H, m), 1.81 (1H, m), 1.16-0.99 (42H, m). <sup>13</sup>C-NMR (75.47 MHz, CDCl<sub>3</sub>): δ 233.3 (3xC, Cr(CO)<sub>3</sub>), 148.6 (C), 141.9 (C), 130.9 (C), 126.2 (CH), 123.5 (CH), 112.1 (CH<sub>2</sub>), 110.3 (C), 107.0 (C), 94.1 (CH), 92.6 (CH), 92.5 (CH), 90.1 (CH), 71.0 (CH), 67.8 (CH), 45.8 (CH<sub>2</sub>), 45.0 (CH<sub>2</sub>), 34.0 (CH<sub>2</sub>), 28.2 (CH<sub>2</sub>), 23.2 (CH<sub>2</sub>), 18.2 (6xCH<sub>3</sub>), 18.1 (6xCH<sub>3</sub>), 12.4 (3xCH), 12.3 (3xCH).

**Tricarbonyl- $\{\eta^6\text{-}[3,4\text{-dihydro-1-}((\text{trifluoromethanesulfonyloxy})\text{naftalen})\}$  chromium(0) (14).**

A solution of lithium diisopropylamide was prepared by slowly addition of a solution of *n*-BuLi in hexanes (0.42 mL, 0.92 mmol, 2.2M, 1.3 equiv) to a -78 °C cooled neat *i*-Pr<sub>2</sub>NH (0.14 mL, 1.01 mmol, 1.4 equiv). The bath was removed and the white slurry was stirred at 23 °C for 15 min. The suspension was cooled to -78 °C and dry THF (2.5 mL) was added. After 15 min, a solution of ketone **9** (0.200 g, 0.71 mmol, 1 equiv) in dry THF (2 mL) was added dropwise. The reaction mixture was stirred at -78 °C for 45 min and a solution of *N,N*-(5-chloropyridin-2-yl)-bistriflimide (0.444 g, 1.13 mmol, 1.6 equiv) in dry THF (1.5 mL) was added via cannula. The mixture was allowed to reach 23 °C. The reaction was quenched by the addition of H<sub>2</sub>O (10 mL). The mixture was extracted with EtOAc (3x10 mL). The combined organic layers were dried, filtered and concentrated. The residue was purified by flash chromatography (10% EtOAc/hexanes) to give **14** [0.215 g, 0.52 mmol, 73%, orange oil, *R<sub>f</sub>* = 0.44 (20% EtOAc/hexanes)]. <sup>1</sup>H-NMR (250 MHz, CDCl<sub>3</sub>): δ 6.02 (1H, m), 5.55 (1H, m), 5.12-5.38 (3H, m), 2.85 (1H, m), 2.40-2.72 (3H, m). <sup>13</sup>C-NMR (63 MHz, CDCl<sub>3</sub>): δ 232 (3xC, Cr(CO)<sub>3</sub>), 124.3 (CH), 120.1 (C), 107.5 (C), 95.7 (C), 92.0 (CH), 91.4 (CH), 89.9 (CH), 86.7 (CH), 25.6 (CH<sub>2</sub>), 21.5 (CH<sub>2</sub>). MS ([CI]<sup>+</sup>, *m/z*, %): 415 ([M+H]<sup>+</sup>, 97), 414 ([M]<sup>+</sup>, 98), 279 ([M+H-Cr(CO)<sub>3</sub>]<sup>+</sup>, 43), 266 ([M+H-OTf]<sup>+</sup>, 96), 147 (100). HMRS ([CI]<sup>+</sup>): calcd for: [C<sub>14</sub>H<sub>10</sub>O<sub>6</sub>F<sub>3</sub>SCr]<sup>+</sup> ([M+H]<sup>+</sup>): 414.9555; found: 414.9559.

**Tricarbonyl- $\{\eta^6$ -(1,2-dihydro-4-[(3*S*,5*R*)-3,5-bis-(*tert*-butyldimethylsilyloxy)-2-methyl-cyclohex-1-en-1-yl]ethynyl)-naftalen} chromium(0) (**16**).** Compound **15** (0.120 g, 0.31 mmol, 1.3 equiv), PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub> (8 mg, 0.011 mmol, 5 mol%) and CuI (2 mg, 0.011 mmol, 5 mol%) were successively added to a solution of **14** (0.100 g, 0.24 mmol, 1 equiv) in dry Et<sub>3</sub>N (3 mL). The reaction mixture was heated at 60 °C for 2 h. The mixture was allowed to reach 23 °C and then filtered through a pad of celite. The solids were washed

with CH<sub>2</sub>Cl<sub>2</sub> (3x5 mL) and the combined solution was washed with a sat NH<sub>4</sub>Cl (20 mL). The aqueous layer was extracted with CH<sub>2</sub>Cl<sub>2</sub> (3x25 mL). The combined organic extracts were dried, filtered and concentrated in vacuo. The residue was purified by flash chromatography (hexanes) to give **16** [0.121 g, 0.187 mmol, 78%, orange oil, *R<sub>f</sub>* = 0.60 (20% EtOAc/hexanes)]. <sup>1</sup>H-NMR (250 MHz, CDCl<sub>3</sub>): δ 6.43 (1H, dd, *J*<sub>1</sub> = 6.0 Hz, *J*<sub>2</sub> = 3.7 Hz), 5.82 (1H, dd, *J*<sub>1</sub> = 6.0 Hz, *J*<sub>2</sub> = 2.2 Hz), 5.45-5.20 (3H, m), 4.24 (1H, m), 4.14 (1H, m), 2.86-2.35 (5H, m), 2.14 (1H, m), 1.98 (3H, s), 1.87 (1H, m), 1.72 (1H, m), 0.92 (9H, s), 0.90 (9H, s), 0.12 (6H, br s), 0.08 (6H, s). <sup>13</sup>C-NMR (63 MHz, CDCl<sub>3</sub>): δ 233.2 (3xC, Cr(CO)<sub>3</sub>), 142.6 (C), 136.7 (CH), 118.9 (C), 114.7 (C), 107.5 (C), 102.2 (C), 92.5 (CH), 92.1 (C), 91.5 (CH), 91.2 (CH), 90.7 (CH), 87.2 (C), 69.8 (CH), 64.1 (CH), 41.1 (CH<sub>2</sub>), 39.4 (CH<sub>2</sub>), 26.0 (CH<sub>2</sub>), 25.9 (3xCH<sub>3</sub>), 25.8 (3xCH<sub>3</sub>), 23.4 (CH<sub>2</sub>), 19.3 (CH<sub>3</sub>), 18.1 (C), 18.0 (C), -4.3 (CH<sub>3</sub>), -4.6 (CH<sub>3</sub>), -4.7 (CH<sub>3</sub>), -4.8 (CH<sub>3</sub>). MS ([CI]<sup>+</sup>, *m/z*, %): 644 ([M]<sup>+</sup>, 13), 560 ([M-3xCO]<sup>+</sup>, 8), 377 ([M-OTBS-Cr(CO)<sub>3</sub>]<sup>+</sup>, 83), 245 [M-H-2TBSO-Cr(CO)<sub>3</sub>]<sup>+</sup>, 100). HMRS ([CI]<sup>+</sup>): calcd for: [C<sub>34</sub>H<sub>48</sub>CrO<sub>5</sub>Si<sub>2</sub>]<sup>+</sup> ([M]<sup>+</sup>): 644.2445; found: 644.2448.

**Tricarbonyl- $\{\eta^6$ -[1,2-dihydro-4*Z*-(3*S*,5*R*)-3,5-bis-(*tert*-butyldimethylsilyloxy)-2-methyl-cyclohex-1-yl]vinyl]-naftalen} chromium(0) (**17**).** A suspension of quinoline in hexanes (50 mL, 2 mmol, 0.04M, 1.25 equiv) and Lindlar catalyst (167 mg, Pd/CaCO<sub>3</sub> poisoned with lead) were successively added to a solution of enyne **16** (0.100 g, 0.16 mmol, 1 equiv) in dry hexanes (27 mL). The system was purged three times with argon and two times with hydrogen. The reaction mixture was stirred under hydrogen at balloon pressure for 1 h and then filtered through a pad of celite. The solids were washed with hexanes and the combined solution was concentrated in vacuo. The residue was purified by flash chromatography (hexanes) to give **16** [0.036 g, 0.06 mmol, 35%, red oil, *R<sub>f</sub>* = 0.70 (20% EtOAc/hexanes)]. <sup>1</sup>H-NMR (250

MHz,  $\text{CDCl}_3$ ):  $\delta$  6.24 (1H, d,  $J = 12.1$  Hz), 6.04 (1H, br s), 5.49-5.19 (5H, m), 4.32-3.85 (2H, m), 2.90-1.20 (11H, m), 0.88 (18H, m), 0.05 (12H, m). MS ( $[\text{Cr}]^+$ , m/z, %): 510 ( $[\text{M}-\text{Cr}(\text{CO})_3]^+$ , 20), 379 ( $[\text{M}-\text{Cr}(\text{CO})_3-\text{OTBS}]^+$ , 86), 355 (49), 247 ( $[\text{M}-\text{H}-2\text{TBSO}]^+$ , 100). HMRS ( $[\text{Cr}]^+$ ): calcd for:  $[\text{C}_{34}\text{H}_{50}\text{CrO}_5\text{Si}_2]^+$  ( $[\text{M}]^+$ ): 646.2602; found: 646.2626.


**(1R,3S,5Z)-5-[(E)-2-(2,3-Dihydronaphthalen-4(1H)-ylidene)ethylidene]-1,3-bis-(tert-butyl dimethylsilyloxi)-4-methylenecyclohexane (4) and (1R,3S)-5-[(Z)-2-(1,2-dihydronaphthalen-4-yl)vinyl]-1,3-bis-(tert-butyl dimethylsilyloxi)-4-methyl-4-cyclohexene (7).** A solution of **17** (0.030 g, 0.046 mmol) in dry isooctane (5 mL) was heated at reflux for 2 h. The reaction was allowed to reach 23 °C and then concentrated *in vacuo*. The residue was re-dissolved in MeOH (3 mL). The resulting solution was cooled at 0 °C and a solution of CAN [ammonium cerium(IV) nitrate] in MeOH (1.5 mL) was added until green color remained. The mixture was extracted with hexanes (3x5 mL). The combined organic extract was washed with  $\text{H}_2\text{O}$  (10 mL), dried, filtered and concentrated *in vacuo*. The residue was purified by flash chromatography (5% EtOAc/hexanes) to afford a mixture of compounds **4b** and **7** [0.016 g, 0.031 mmol, 68%, ca 1:0.7, colorless oil,  $R_f = 0.70$  (5% EtOAc/hexanes)].  $^1\text{H-NMR}$  (250 MHz,  $\text{CDCl}_3$ ):  $\delta$  7.54 (H15-**4b**, d,  $J = 7.7$  Hz), 7.22-7.04 (Hs-Ar, br m), 6.99 (H7-**4b**, d,  $J = 11.3$  Hz), 6.34 (H6-**4b**, d,  $J = 11.3$  Hz), 6.21 (H7 + H6-**7**, d,  $J = 12.2$  Hz), 5.98 (H9-**7**, t,  $J = 4.7$  Hz), 5.31 (H19-**4b**, s), 4.95 (H19-**4b**, d,  $J = 2.2$  Hz), 4.46 (H1-**4b**, m), 4.30-3.89 (H3-**4b**, H1-**7**, H3-**7**, m), 2.88-1.50 (Hs-**4+7**, m), 0.93-0.78 (*t*-BuSi + Me19-**7**, m), 0.14-0.03 (MeSi, m).

## RESULTS AND DISCUSSION

Complex **9** was prepared according to Schmalz's procedure (Figure 3) (Schmalz et al. 1992). Reduction of ketone **6** with sodium borohydride

in methanol provided alcohol **10** in 98% yield. Heating at reflux a mixture of **10** and chromium hexacarbonyl in *n*-heptane/*n*-Bu<sub>2</sub>O/THF (10:10:1) gave the diastereomeric alcohols **11** in 39% yield, which upon oxidation with Ac<sub>2</sub>O and DMSO produced the desired Cr(CO)<sub>3</sub>-complex **9** in 84% yield. Wittig-Horner coupling between ketone **9** and phosphine oxide anion **5** in THF furnished a mixture of four diastereomers (**12+13**), which could be separated by HPLC [**12** (two diastereomers 0.7% + 5.5%); **13** (two diastereomers 0.5 + 1.7%)] together with recovered starting ketone **9** (64%). Each pair of diastereomers could not be distinguished by  $^1\text{H NMR}$  (500 MHz). The H7 and H15 of **12** appear deshielded with respect to those corresponding to **13** (steroid numbering is used for discussion). The structure **12** was established by  $^1\text{H NMR}$  nOe analysis.

Though the Cr(CO)<sub>3</sub>-complexation reduces conjugation of the aromatic unit with the carbonyl group, the yield on Wittig-Horner reaction products is still too low to consider this approach of preparative value. This result led us to examine the dienyne approach (route **B**, Figure 2) as an alternative pathway to the target compound **4b** (Figure 4). Treatment of ketone **9** with LDA followed trapping of the resulting enolate with 2-[*N,N*-bis(trifluoromethylsulfonyl)-amino]-5-chloropyridine afforded vinyl triflate **14** (73%), which upon Sonogashira coupling (Sonogashira et al. 1998) with enyne **15** in the presence catalytic amounts of CuI and PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub> provided the dienyne **16** (68%). Semihydrogenation of the triple bond in the presence of Lindlar catalyst and quinoline in hexanes gave the previtamin **D 17** in 35% yield. Finally, thermal sigmatropic [1,7]-H shift on **17** in refluxing isooctane followed by Cr(CO)<sub>3</sub>-decomplexation with ammonium cerium(IV) nitrate in methanol gave a 1:0.7 mixture of the target protected vitamin **4b** and the corresponding previtamin **7** in 68% yield. The formation of the previtamin **7** can be rationalized



**Figure 3** - Effect of  $\text{Cr}(\text{CO})_3$ -complexation on the Wittig-Horner coupling.

by vitamin D-previtamin D equilibration during thermal sigmatropic rearrangement. Deprotection of **4b** (TBAF, THF) gave the corresponding vitamin D compound (95%), which equilibrates with its previtamin D form on standing in  $\text{CDCl}_3$  as determined by  $^1\text{H-NMR}$  (vitamin D/previtamin D ratio = 1/2.2, equilibration time = 120 h, room temperature).


### CONCLUSIONS

In summary, we have demonstrated that the dienyne route is suitable for the synthesis of vitamin D analogs with aromatic **D**-ring for biological evaluation. The key feature of the synthesis is the complexation of the aromatic **D**-ring with  $\text{Cr}(\text{CO})_3$  to partially release conjugation with the previtamin triene system, thus allowing the thermal sigmatropic [1,7]-H shift to generate the desired vitamin D form. The formation of  $\text{Cr}(\text{CO})_3$ -complexed vitamin D derivatives opens the way to a novel class of VDR-ligands for biological testing.

(Spectral data ( $^1\text{H}$  and  $^{13}\text{C}$  NMR) of all compounds - Supplementary Material)

### ACKNOWLEDGMENTS

We thank Xunta de Galicia (project GPC2014/001) and for financial support. Silvina Eduardo thanks the Spanish MEC for a fellowship. Rita Sigüeiro



**Figure 4** - Effect of  $\text{Cr}(\text{CO})_3$ -complexation on the sigmatropic [1,7]-H shift.

thanks Xunta de Galicia for a post-doctoral fellowship (Axudas posdoutorais, plan I2C, mod B).

### REFERENCES

- BOUILLON R, OKAMURA WH AND NORMAN AW. 1995. Structure function relationships in the vitamin D endocrine system. *Endocr Rev* 16: 200-257.
- CASTEDO L, MOURIÑO A AND SARANDESES LA. 1986. Palladium-catalyzed synthesis of dienynes related to vitamin D from enoltriflates. *Tetrahedron Lett* 27: 1523-1526.
- EDUARDO-CANOSA S, FRAGA R, SIGÜEIRO R, MARCO M, ROCHEL N, MORAS D AND MOURIÑO A. 2010. Design and synthesis of active vitamin D analogs. *J Steroid Biochem Mol Biol* 121: 7-12.
- EVANS RM. 1988. The steroid and thyroid hormone receptor superfamily. *Science* 240: 889-895.
- FELDMAN D, GLORIEUX FW AND PIKE JW. 1997. Vitamin D. Academic, New York, 1997.
- FELDMAN D, PIKE JW AND ADAMS JS (Eds). 2011. Vitamin D, 3<sup>rd</sup> ed., London, U.K. Academic Press.
- GLEBOCKA A AND CHIellini G. 2012. A-Ring analogs of 1,25-dihydroxyvitamin D<sub>3</sub>. *Arch Biochem Biophys* 523: 48-57.
- KENSLER TW, DOLAN PM, GANGE SJ, LEE JK, WANG Q AND POSNER GH. 2000. Conceptually new deltanoids (vitamin D analogs) inhibit multistage skin tumorigenesis. *Carcinogenesis* 21: 1341-1345.
- KLIEWER SA, UMESONO K, MANGELSDORF DJ AND EVANS RM. 1992. Retinoid X receptor interacts with nuclear receptors in retinoid acid, thyroid hormones and vitamin D<sub>3</sub> signaling. *Nature* 355: 446-449.
- LINCOLN MR ET AL. 2010. A ChIP-seq defined genome-wide map of vitamin D receptor binding: associations with disease and evolution. *Genome Res* 20: 1352-1360.

- LYTHGOE B. 1980. Synthetic approaches to vitamin D and its relatives. *Chem Soc Rev* 9: 449-475.
- MA Y, YU WD, HIDALGO AA, LUO W, DELANSORNE R, JOHNSON CS AND TRUMP DL. 2013. Inecalcitol, an analog of 1,25D<sub>3</sub>, displays enhanced antitumor activity through the induction of apoptosis in a squamous cell carcinoma model system. *Cell Cycle* 12: 743-752.
- MOLNAR F ET AL. 2011. 1 $\alpha$ ,25(OH)<sub>2</sub>-3-Epi-vitamin D<sub>3</sub>, a natural physiological metabolite of vitamin D<sub>3</sub>: its synthesis, biological activity and crystal structure with its receptor. *PLoS ONE* 6(3): e18124.
- NORMAN AW. 1979. Vitamin D the Calcium Homeostatic Steroid Hormone, Academic Press, New York.
- OTERO R, SEOANE S, SIGÜEIRO R, BELORUSOVA AY, MAESTRO MA, PÉREZ-FERNÁNDEZ R, ROCHEL N AND MOURIÑO A. 2016. Carborane-based design of a potent vitamin D receptor agonist. *Chem Sci* 7: 1033-1037.
- PLUM LA AND DELUCA HF. 2010. Vitamin D, disease and therapeutic opportunities. *Nat Rev Drug Discovery* 9: 941-955.
- PLUM LA, PRAHL JM, MA X, SICINSKI RR, GOWLUGARI S, CLAGETT-DAME M AND DELUCA HF. 2004. Biologically active noncalcemic analogs of 1 $\alpha$ ,25-dihydroxyvitamin D with an abbreviated side chain containing no hydroxyl. *Proc Natl Acad Sci USA* 101: 6900-6904.
- SCHMALZ HG, MILLIES B, BATS JW AND DÜRNER G. 1992. Diastereoselective complexation of temporarily chryrally modified ligand: enantioselective preparation and configurational assignment of synthetically valuable  $\eta^6$ -tricarbonylchromium-1-tetralone derivatives. *Angew Chem Int Ed* 31: 631-633.
- SONOGASHIRA K. 1998. Metal-catalyzed cross-coupling reactions. Diederich F and Stang PJ (Eds), Wiley-VCH: Weinheim, Germany, p. 203-229.
- VERLINDEN L, VERSTUYF A, VAN CAMP M, MARCELIS S, SABBE K, ZHAO XY, DE CLERCQ P, VANDEWALLE M AND BOUILLON R. 2000. Two novel 14-epi-analogues of 1,25-dihydroxyvitamin D<sub>3</sub> inhibit the growth of human breast cancer cells *in vitro* and *in vivo*. *Cancer Res* 60: 2673-2679.
- YAMADA S AND MAKISHIMA M. 2014. Structure-activity relationship of nonsecosteroidal vitamin D receptor modulators. *Trends in Pharmacol Sci* 35: 324-337.
- ZHAO Q, CURRAN DP, MALACRIA M, FENSTERBANK L, GODDARD JP AND LACÔTE E. 2012. NHC-Catalyzed chemo- and regioselective hydrosilylation of carbonyl derivatives. *Synlett* 2012: 433-437.

#### SUPPLEMENTARY MATERIAL

Spectral data (<sup>1</sup>H and <sup>13</sup>C NMR) of all compounds.